STEMI Treated With Primary Angioplasty and Intravenous Lovenox or Unfractionated Heparin (UFH)
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
Randomized evaluation of enoxaparin (0.5mg/kg IV) versus UFH (50-70IU/kg with GPIIb/IIIa
inhibitors; 70-100IU without GPIIb/IIIa inhibitors). Anticoagulation can be continued after
the procedure using the same agents as those allocated per randomization (enoxaparin SC, UHF
IV or SC)